The nasal type of extranodal natural killer/T-cell lymphoma is a rare aggressive lymphoma with poor prognosis. To discover a successful treatment, we investigated the efficacy and safety of chemotherapy with methotrexate, etoposide, dexamethasone, and polyethylene glycolasparaginase (MESA). Three cycles of MESA were administered to 46 patients with new or relapsed/refractory natural killer/T-cell lymphoma. Complete response after 3 treatment cycles was 43.5%, the overall response rate was 87%, and 2-year overall survival was 83.4%. Complete response was significantly better for newly diagnosed patients than for patients with relapsed/ refractory disease. Patients with newly diagnosed disease had a significantly better overall response rate after 1, but not after 2 or 3 treatment cycles. Overall survival and progression-free survival did not differ over 2 years. Grade 1/2 toxicities were frequent, but MESA was associated with fewer grade 3/4 events or treatment-related deaths. These results will require confirmation in larger prospective trials.
Recently, novel regimens have been tested, with promising results.
One of the new first-line therapies for NKTCL is dexamethasone, methotrexate, ifosfamide, etoposide, and L-asparaginase (SMILE) chemotherapy. 19 The SMILE therapy is associated with overall response rates (ORRs) ranging from 60% to 80%. [19] [20] [21] [22] However, SMILE has resulted in a high level of hematologic toxicities, such as grade 3/4 neutropenia, thrombocytopenia, and nephrotoxicity. 23 Asian patients may be at higher risk of hematologic toxicity as 1 study 24 reported 92% of patients had grade 4 neutropenia. Asian and non-Asian patients also experienced other non-hematologic events such as hyperbilirubinemia and fibrinogenemia. 19, 21, 22, 24, 25 These adverse events are frequently accompanied by hypersensitivity to L-asparaginase. 21, 22, 26, 27 This enzyme is a key component of chemotherapy because of the selective inability of transformed lymphocytes to synthesize asparagine. 28 A recent review of the literature indicates that an allergic reaction to L-asparaginase occurs in up to half of patients who receive this compound. 27 Thus, to explore the possibility of more effective and less toxic chemotherapy for NKTCL, we have formulated methotrexate, etoposide, dexamethasone, and polyethylene glycol-asparaginase (MESA), a novel chemotherapeutic regimen containing methotrexate, etoposide, dexamethasone, and polyethylene glycol-asparaginase (pegaspargase).
These agents are not affected by multidrug resistance and may be key drugs for first-and second-line treatments for NKTCL. We omitted ifosfamide, which is included in the SMILE protocol, as NKTCL may develop resistance to the drug. Polyethylene glycol-asparaginase is a monoethoxypolyethylene glycol succinimidyl conjugate of Lasparaginase produced in Escherichia coli. This form of asparaginase has advantages over other sources because it is more stable and less likely to trigger an immune reaction. 29, 30 It has been reported that the incidence of allergic reaction is as high as 30% after L-asparaginase treatment. 31 Studies have found that pegaspargase has similar efficacy as L-asparaginase in treating acute lymphoblastic leukemia in children [32] [33] [34] [35] and has about a 5 times longer half-life with therapeutic effects being maintained for about 2 weeks. 23, 36, 37 Polyethylene glycol-asparaginase also requires lower and less frequent dosing. 36 Therefore, the use of pegaspargase may reduce the pain due to continuously intravenous infusion, decrease hospital stay, and increase therapeutic compliance. Other drugs included in MESA, etoposide and steroid hormones, are effective treatments for hemophagocytic syndrome, which can be a concomitant disease in patients with NKTCL. Here, we report the findings of a multicenter study to evaluate the initial outcomes of a MESA regimen and involved-field radiotherapy (RT). We assessed its effectiveness, toxicity, and feasibility in Asian patients with newly diagnosed, relapsed, or refractory NKTCL. 
| Diagnosis of pathology
Morphological analysis of the tissue samples was performed on formalin-fixed, paraffin-embedded tissue sections. A panel of primary antibodies specific to leukocyte common antigen, cluster of differentiation (CD)3, CD20, CD79a, CD56, cytotoxic granule-associated RNA binding protein (TIA1), granzyme B, and Ki-67 (DAKO, Glostrup, Denmark) was used. Immunohistochemical staining was performed with the EnVision System and the DAB Detection System (DAKO).
The primary antibody was substituted with phosphate-buffered saline (PBS) as a negative control.
DNA from paraffin-embedded tissue was prepared with a tissue DNA extraction and purification kit (Dneasy Tissue Kit, Qiagen, GmbH, Hilden, Germany). Two sets of primers were used to amplify the rearranged T-cell receptor gene in accordance with the BIOMED-2 system as previously described. 39 The positive control was a sample from a case of T-cell lymphoma with a known monoclonal rearrangement; the negative control, run simultaneously, was a reaction without template DNA.
The fluorescent in situ hybridization probe for Epstein-Barr virus (EBV)-encoded RNA (EBER) and the fluorescent in situ hybridization kit were purchased from DAKO. The probe was a single-stranded DNA probe that binds to EBER1 and EBER2. The kit provides a known positive control. A known negative sample from a reactive hyperplasia of lymph node tissue served as a negative control, and the blank control was phosphate-buffered saline substituted for hybridization buffer. A positive cell had brown product in the nucleus, but cytoplasmic and membrane staining was regarded as negative. 
| Chemotherapeutic regimen and eligibility criteria
All patients included have newly diagnosed, relapsed, or refractory NKTCL. The inclusion criteria were as follows: (1) Methotrexate-etoposide-dexamethasone-pegaspargase chemotherapy was administrated as summarized in Table 1 The decision to receive HSCT was made at the discretion of the treating physician and the patient on the basis of the patient's age and condition. 
| Response and toxicity criteria

| Statistical analysis
The primary end points were CR, PR, and ORR (ORR = CR + PR) after 3 treatment cycles. The secondary end points were OS, PFS, and toxicity.
The duration of OS was defined as the time interval between enrollment and the death of the patient or, for patients who were censored, the date of the last follow-up. PFS was calculated from the time of enrollment to the day that progression was first identified, the time of death, or the date of the last follow-up.
Overall survival and PFS were estimated by using the KaplanMeier method. For effectors of OS and PFS, the hazard ratio and the 95% confidence interval were estimated by using a Cox proportional hazard model. The log-rank test or the Breslow test was implemented to compare differences in OS and PFS. All analyses were performed by using SPSS 22 software (IBM Corporation, Armonk, New York).
3 | RESULTS
| Patient characteristics
This study enrolled 46 patients, whose clinical characteristics are summarized in 
| Response
After 3 treatment cycles, 20 of 46 patients (43.5%) had CR, 20 (43.5%) had PR, and 6 (13%) had no response. The ORR was 87%.
As compared with patients with refractory or relapsed disease, those with newly diagnosed NKTCL had a significantly higher rate of CR (54.3% vs 9.1%, P = .013) and lower rate of PR (34.3% vs 72.7%) (Table 3) . Despite these differences, the ORRs were similar for the 2 treatment groups of patients. The responses of patients by stage of disease, IPI, and Ki-67 expression are reported in Table 4 . Although patients with stage I disease tended to have a higher CR and lower PR rates than did those with stage II or above, the differences did not reach statistical significance. Likewise, no significant differences were found in the rates of CR or PR between patients with different IPI scores or those whose tumors had ≤60% or >60% cells that were positive for Ki-67.
| Prognostic factors and survival
Four patients died (8.7%) from hemophagocytic syndrome. Across the patients, there were 13 events of disease progression. For both OS and PFS, no events were reported after 1 year of follow-up. Five patients were lost to follow-up within 1 year because of lack of efficacy or financial difficulty. In addition, 5 to 7 patients discontinued;
they only finished 1 course of therapy and therefore did not meet the requirement of completing at least 3 courses of therapy. The mean duration of follow-up was 12.3 ± 7.5 months (range:
2-24 months) for OS and 10.7 ± 7.2 months (range: 0-24 months)
for PFS.
The results of univariate analyses of OS and PFS are shown in Table 5 . None of the factors that were examined were significantly associated with OS or PFS. Because of the limited number of patients and the lack of significance of effectors of OS and PFS in the univariate analysis, multivariate analysis was not performed.
The rates of OS and PFS for the study population are illustrated in Figures 1A and 2A , respectively. The 2-year OS and PFS rates were 83.4% and 66%, respectively. Although we found no significant differences between groups, we determined that patients with refractory or relapsed disease had a lower 2-year OS rate ( Figure 1B with an IPI score of 0, 1, or, ≥ 2, the 2-year OS was 90.9%, 85.7%, and 76.6%, respectively (P = .861), while the 2-year PFS was 80%, 71.4%, and 51.9% (P = 0.160). Among patients whose tumors had ≤60% and >60% Ki-67-positive cells, the 2-year survival was 75.0% and 89.7%, respectively (P = .338) and the 2-year PFS was 61% and 65.2% (P = .825). (Table 6 ).
| Toxicity
| DISCUSSION
Although the addition of L-asparaginase to standard chemotherapy regimens for NKTCL has improved survival, hypersensitivity remains a problem for many patients. In this report, we present the results of a phase 2 trial that assessed the efficacy and safety of MESA chemotherapy with or without RT or HSCT for treating NKTCL. We found MESA showed efficacy in treating NKTCL and was associated and was well tolerated. Therefore, this regimen has potential as a new firstor second-line treatment for NKTCL and supports its further evaluation in treating NKTCL.
Our findings for first-line treatment for NKTCL compares favorably with those of other clinical trials that assessed different treatment regimens in stage I/II newly diagnosed NKTCL. Three studies using simultaneous chemoradiotherapy 42-45 and 3 assessing chemotherapy followed by RT [46] [47] [48] had ORRs of 78% to 96%, 2-year OS rates of 78% to 88%, and 3-year OS rates of 54% to 86%. The newly diagnosed patients in our study had an ORR of 88% and a 2-year OS rate of 84%.
In addition, there were no treatment-related deaths in our study.
In our study, not all patients received RT. A recent meta-analysis has suggested that chemoradiotherapy results in better 3-year survival than chemotherapy alone. 6 Methotrexate-etoposide-dexamethasonepegaspargase also performed at least as well as other first-line treatments that also did not include RT. Studies evaluating SMILE, ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) and gemcitabine, pegaspargase, cisplatin, and dexamethasone chemotherapies yielded ORRs ranging from 55% to 100%. 20, 21, [49] [50] [51] When assessing second-line treatments, MESA therapy showed an efficacy similar or better to prior studies. A phase 2 study that evaluated the efficacy and safety of SMILE therapy showed an excellent antitumor activity for patients with relapsed or refractory NKTCL, with an ORR of 77% and a 1-year OS of 79% or 25%, respectively, and with a 3-year OS of 50%. Patients in this trial achieved an ORR of 76% and a 1-year OS of 69%.
The treatment protocols for the MESA and MEDA trials differed in 2 key aspects: first, the doses of methotrexate and dexamethasone were not equivalent; second, the treatment was distributed over 5 days in our trial and 4 days in the Ding et al study. In our trial, the 11 patients with relapsed or refractory disease had an ORR of 81% and a 1-year OS of 81.8%.
The adverse events experienced by patients in this trial were generally less severe than those of other studies and supports the use of MESA chemotherapy as a new first-or second-line therapy for NKTCL.
Although grade 1 and 2 toxicities were frequent, grade 3 events were few and there were no grade 4 events or treatment-related deaths.
Moreover, pegaspargase was well tolerated by all patients.
The number of grade 3 or 4 toxicities of this trial was less than that of the MEDA trial. 55 As the treatment protocols of our trial and the MEDA trial were not the same (see above), the differences in adverse events highlight the importance of determining an optimal treatment regimen either through retrospective analysis of completed trials or prospective analysis of additional patients in randomized controlled trials. Future studies should also include subtype analysis of distinct patient populations, as our trial enrolled newly diagnosed patients with stage I or II disease and the MEDA trial did not. However, in the study by Kwong et al, adverse events were not more frequent in those with relapsed/refractory disease. 21 Among the trials of SMILE chemotherapy, the rates of adverse events and treatment-related deaths were much higher than those of the MEDA and MESA trials, even reaching 100% for some types of toxicities. 19, 21, 22 In a study of IMEP, the rates of hematologic toxicities were also higher. 47 SMILE, MESA, and IMEP are similar treatments, varying only in the use of ifosfamide, and prednisolone. Given this similarity, randomized controlled trials of these 3 regimens should be undertaken to confirm the superior safety outcomes of MESA chemotherapy. Kurtzberg and colleagues have found that, in patients with acute lymphoblastic leukemia, inclusion of either conjugated or native asparaginase showed no differences in adverse events 56 ; therefore, the divergent safety profiles of MESA, SMILE, and IMEP may be related to ifosfamide. It is possible that any differences in clinical response and safety profile between the MESA, SMILE, and IMEP protocols may also be due to differences in the dose of chemotherapy administered, which was not evaluated in our study.
Our results highlight the need to characterize prognostic factors for patients with nasal-type NKTCL treated with new and emerging chemotherapy regimens. Although patients whose tumors had ≥60% cells positive for Ki-67 had a lower 3-cycle rate of CR and lower 1-year The Breslow test found no differences among the groups (P = .656 for stage, P = .160 for IPI, and P = .825 for Ki-67 expression). Abbreviations: IPI, international prognostic index; PFS, progression-free survival OS and PFS than did those whose tumors had <60% positive cells, the results were not statistically significant, and univariate analysis determined that a high Ki-67 expression was not associated with a poor survival. This finding differs from those of previous studies. [57] [58] [59] [60] [61] [62] Similarly, IPI score, disease stage, and expression of β2-microglobulin and CD56, which have all been shown to be associated with survival for patients with nasal or extranasal NKTCL, 59, [63] [64] [65] [66] were not associated with survival in our study. Additional research will be needed to determine which clinicopathological factors best predict the success of MESA chemotherapy.
This study had several limitations. First, the clinical trial is still ongoing, and this report is the initial summarization of the clinical findings. Second, the short follow-up and the retrospective design of the study may have influenced our results. The fact the study was retrospective limits the type and quality of the data available for analysis.
Third, the patient population is heterogeneous as we recruited patients receiving initial treatment and those receiving treatment due to recurrence, with localized disease patients as well as stage III/IV disease patients. Prospective studies with a larger sample size and long-term follow-up will be needed to confirm the therapeutic efficacy in these patients.
In conclusion, we have conducted a phase 2 trial of a new chemotherapy regimen, MESA, in hopes of identifying a treatment that achieves the superior outcomes of SMILE therapy without the accompanying toxicities. Our results demonstrate that MESA is a highly effective and safe chemotherapy regimen for patients with newly diagnosed, relapsed, or refractory NKTCL. Careful patient monitoring is needed, because the MESA regimen, like all chemotherapies, is potentially toxic. Additional studies in an expanded patient population should be conducted to define an optimal treatment protocol and to determine if the risk/benefit profile is similar for non-Asian patients. 
